Search Results

• October 2021: TFTEST – Temporary Change in Performing Send-out Laboratory

  Beginning October 25, 2021, Testosterone, Total and Free, Serum (TFTEST) will be temporarily sent to an alternate reference laboratory.

• September 2021: New Test – Beta(β)-D-Glucan Assay

  This FDA-approved assay diagnoses certain systemic fungal infections and supports anti-fungal therapy responses in hospitalized patients.

• September 2021: Ziad Peerwani, MD Appointed as Medical Director of Cleveland Clinic Laboratories

  Ziad Peerwani, MD has been appointed as the new Medical Director for Cleveland Clinic Laboratories, effective September 1, 2021.

• Pathology Insights – Mammary Myofibroblastoma: A Practical Approach with Miglena Komforti, DO

  Dr. Komforti discusses histopathologic findings, ancillary immunohistochemical stains, & clinical significance of mammary myofibroblastoma.

• August 2021: Changes to Specimen Requirements, Reference Ranges, and Test Builds

  All changes listed are effective August 16, 2021. Questions? Please contact Client Services at 800.628.6816.

• July 2021: Test Menu Optimization & Discontinuations – MGLESE, MYSGRV, PARSYN

  A recent review has identified tests that will be discontinued in favor of more simple, focused, and cost-effective testing options.

• July 2021: Immediate Test Discontinuation – Hepatitis A Antibody, Total (AHAVT)

  Due to vendor reagent being on backorder, AHAVT’s initially scheduled discontinuation on August 7 has been expedited to July 1, 2021.

• Pathology Insights – Diagnosis of Oncocytic Salivary Gland Tumors with Mobeen Rahman, MD

  The diagnosis of oncocytic salivary gland tumors can be challenging, especially on core needle biopsies; Dr. Mobeen Rahman discusses.

• June 2021: Send-Out Test Discontinuation – Complement Factor B (C3PA)

  This test is no longer offered by the performing reference laboratory. At this time, there is no recommended replacement test.

• CC-SIGN® Head & Neck Gene Fusion Next-Generation Sequencing Panel

  This customized, 30-gene NGS panel is intended for use in the diagnosis and management of benign and malignant tumors of the head and neck.

• Pathology Insights – NUT Carcinoma with Sanjay Mukhopadhyay, MD

  In this video, Dr. Mukhopadhyay draws attention to an immunohistochemical profile that can serve as a tip-off to the correct diagnosis.

• May 2021: Non-Sterile Aliquot Tubes – Back In Stock

  As of May 25, 2021, Sarstedt aliquot tubes are back in stock. Laboratory supply orders can be placed by clients on the Supply Storefront.

• May 2021: National Supply Shortage of Light Blue Coagulation Tubes

  There is a severe nationwide shortage of light blue sodium citrate blood collection tubes used for coagulation laboratory tests.

• Pathology Insights – Diagnosis of CD30+ T-cell Lymphoproliferative Disorders with Genevieve Crane, MD, PhD

  The diagnosis of CD30+ T-cell lymphoproliferative disorder can present challenges. In this video, Dr. Genevieve Crane discusses.

• April 2021: Changes to AIDYSA, ENCSER, PARNEO, LAMBRT, & MYGRAV Panels

  Changes listed here are effective May 11, 2021. Questions? Please contact Client Services at 800.628.6816 for assistance.

• Pathology Insights – Two Diagnoses in One Bone Marrow with Megan Nakashima, MD

  Analysis of a bone marrow requires both careful morphologic examination as well as appropriate ancillary studies; Dr. Nakashima discusses.

• Restrictions to PSA and β-HCG, Plasma Add-On Orders

  Due to a potential for falsely-increased results from carryover on analytical laboratory instrumentation, add-on orders are restricted.

• Pathology Insights – Diagnosing Microinvasive Breast Cancer with Miglena Komforti, DO

  In the breast, the pathologic diagnosis of a small focus of invasion can be quite challenging; Dr. Miglena Komforti discusses.

• February 2021: Inhibin B – Changes to Reference Ranges

  A recent change increases the detection of inhibin B in all clinically relevant cases and expands the testing range to improve sensitivity.

• Pathology Insights – Diagnosis of Metastatic Renal Cancer with Sean Williamson, MD

  Pathologic diagnosis can be challenging in the setting of poorly-differentiated and metastatic renal cancer; Dr. Williamson discusses.

• November 2020: Temporarily Unavailable – Stool Gastrointestinal Panel by PCR

  Beginning November 13, 2020, Stool Gastrointestinal Panel by PCR (STGIPR) testing is temporarily unavailable to order from CCL.

• COVID-19: Supply Constraints Affecting Enteric Bacterial Panel by PCR Testing

  Due to supply constraints related to COVID-19, supplies for Enteric Bacterial Panel by PCR (STLPCR) testing are in extremely limited supply.

• COVID-19: Unacceptable Specimen Transport Media for COVID-19 Testing

  Due to incompatibilities with our COVID-19 testing laboratory equipment, Beaver Biomedical VTM and NEST Solution are not accepted by CCL.

• COVID-19: Supply Shortages Impacting Gonorrhea, Chlamydia, and Trichomoniasis Testing

  As a result of supply shortages, Cleveland Clinic Laboratories may periodically be unable to provide Aptima® Urine Specimen Collection Tubes.

• August 2020: Update – Cytogenetic Karyotyping & Chromosomal Microarray Testing

  Starting August 24, 2020, cytogenetic karyotyping and chromosomal microarray testing will temporarily be sent out to a reference laboratory.

• August 2020: Anti-cardiolipin IgM, IgA, and IgG Reporting

  Effective 9/3/2020, Anti-cardiolipin IgM, IgA, and IgG semi-quantitative enzyme immunoassays will be reported with updated reference ranges.

• Antibody Testing for COVID-19: Overview & FAQs

  Learn more from Kamran Kadkhoda, PhD, Medical Director of Immunopathology, and Serpil Erzurum, MD, Chair of the Lerner Research Institute.

• Respiratory Virus Testing

  Cleveland Clinic Laboratories offers COVID-19, Flu, & RSV testing services to healthcare organizations & providers.

• October 2019: Changes to Specimen Requirements, Reference Ranges, and Test Builds

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• Pathology Insights – Pathology of Vaping-Associated Lung Injury with Sanjay Mukhopadhyay, MD

  In this episode of Pathology Insights, Sanjay Mukhopadhyay, MD discusses the findings of a study on the lung pathology of vaping.

• September 2019: Updates to Testosterone, Free & Total, Testing and Reporting

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• September 2019: Changes to Lp-PLA2 Activity Reference Ranges

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• August 2019: Changes to PARNEO, FTESTO Testing

  Additional information will be included in a future Technical Update. Questions? Please contact Client Services.

• July 2019: Changes to NCYTO, URCAT2, MYOSPL, RUFIN, LIVFIB, & AJPWO Testing

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• June 2019: Changes to UALDOS, TSIG, TRAB

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• May 2019: Changes to Reference Ranges & Test Builds

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• May 2019: Upcoming Test Changes, Updates, and Discontinuations

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• March 2019: Changes to PR1433, GM1BM, OMEGAC

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• March 2019: Changes to Acceptable Clobazam (CLOBAZ) Specimen Types

  Effective immediately, plasma is no longer an acceptable specimen type for Clobazam testing; serum from a gel tube remains unacceptable.

• March 2019: Changes to IgG Subclass Reference Ranges

  Effective March 2, 2019, reference ranges for IgG Subclasses 1 & 4 will be changed; all other IgG subclass reference ranges will be the same.

• CC-SIGN® NTRK Plus Gene Fusion Next-Generation Sequencing Panel

  CC-SIGN® NTRK Plus Gene Fusion NGS Panel is designed to detect fusion events in NTRK1, NTRK2, and NTRK3, regardless of fusion partner.

• CC-SIGN® Solid Tumor Gene Fusion Next-Generation Sequencing Panel

  This customized, 59-gene NGS-based panel is intended for use in the diagnosis and management of benign and malignant mesenchymal tumors.

• December 2018: Changes to RETAB, IA2AB, and PNHPNL Testing

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• Pathology Insights – Pleural Fluid: Cyto-Histo Correlation by Sanjay Mukhopadhyay, MD and Charles Sturgis, MD

  A cytopathologist and a thoracic pathologist discuss their diagnostic approach on a case involving pleural fluid cytology and pleural biopsy.

• November 2018: Changes to Vitamin B12 (B12) Testing

  Any additional information will be included in a future Technical Update. Please contact Client Services for assistance.

• November 2018: Changes to Melatonin (MELAT) Testing

  Effective immediately, several changes have been made to Melatonin (MELAT), including container, collection, transport temperature.

• October 2018: Changes To COMPC1, COMP3A, & COMP4A Testing

  Effective November 5, 2018, Complement C 1 (COMPC1), Level 3A (COMP3A), Level 4A (COMP4A) will have several changes implemented.

• October 2018: Changes to ASPIGG, GAL3, HV6ABS, LIDO, & PROPA Testing

  Several upcoming changes to our test directory will affect multiple tests. Please refer to the information below for details.

• QuantiFERON-TB Gold Plus (QTB-Plus) 4-Tube Assay

  Effective September 12, CCL will convert to the QuantiFERON-TB Gold Plus (QTB-Plus) 4-Tube Assay for Mycobacterium tuberculosis testing.

• August 2018: Changes to ADRENL & RICKGM Testing

  Effective September 10, Rickettsia Antibodies IgG & IgM (RICKGM) will be discontinued. Adrenal Antibody (ADRENL) will have several changes.